melatonin has been researched along with Diabetic Cardiomyopathies in 11 studies
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin is a hormone produced by the pineal gland, and it has extensive beneficial effects on various tissue and organs; however, whether melatonin has any effect on cardiac fibrosis in the pathogenesis of diabetic cardiomyopathy (DCM) is still unknown." | 7.96 | Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. ( Che, H; Dong, R; Li, H; Li, Y; Liu, Y; Lv, J; Sahil, A; Wang, L; Wang, Y; Xue, H; Yang, Z, 2020) |
| "Melatonin is a hormone produced by the pineal gland, and it has extensive beneficial effects on various tissue and organs; however, whether melatonin has any effect on cardiac fibrosis in the pathogenesis of diabetic cardiomyopathy (DCM) is still unknown." | 3.96 | Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. ( Che, H; Dong, R; Li, H; Li, Y; Liu, Y; Lv, J; Sahil, A; Wang, L; Wang, Y; Xue, H; Yang, Z, 2020) |
| "Melatonin is a pineal-produced indole known for its anti-aging, antiapoptotic and antioxidant properties." | 2.66 | Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathy. ( Song, YJ; Wu, W; Zhong, CB, 2020) |
| "Melatonin was injected intraperitoneally at a dose of 50 mg/kg/day for 56 days to group 4." | 1.51 | Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway. ( Güntekin, Ü; Kandemir, YB; Tosun, V, 2019) |
| "Melatonin was injected intraperitoneally at a dose of 50 mg/kg/day for 56 days to group 3 and group 4." | 1.48 | Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). ( Behram Kandemir, Y; Bozdemir, MN; Guntekin, Ü; Korucuk, N; Tosun, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, K | 1 |
| Luo, X | 1 |
| Zhong, Y | 1 |
| Deng, L | 1 |
| Feng, J | 2 |
| Che, H | 1 |
| Wang, Y | 4 |
| Li, H | 1 |
| Li, Y | 1 |
| Sahil, A | 1 |
| Lv, J | 1 |
| Liu, Y | 1 |
| Yang, Z | 1 |
| Dong, R | 1 |
| Xue, H | 1 |
| Wang, L | 1 |
| Song, YJ | 1 |
| Zhong, CB | 1 |
| Wu, W | 1 |
| Yu, LM | 1 |
| Dong, X | 1 |
| Xue, XD | 1 |
| Xu, S | 1 |
| Zhang, X | 1 |
| Xu, YL | 1 |
| Wang, ZS | 1 |
| Gao, H | 1 |
| Liang, YX | 1 |
| Yang, Y | 1 |
| Wang, HS | 1 |
| Zhang, M | 2 |
| Lin, J | 2 |
| Wang, S | 2 |
| Cheng, Z | 2 |
| Hu, J | 2 |
| Wang, T | 2 |
| Man, W | 1 |
| Yin, T | 1 |
| Guo, W | 1 |
| Gao, E | 1 |
| Reiter, RJ | 2 |
| Wang, H | 2 |
| Sun, D | 2 |
| Xiong, FY | 1 |
| Tang, ST | 1 |
| Su, H | 1 |
| Tang, HQ | 1 |
| Jiang, P | 1 |
| Zhou, Q | 1 |
| Zhu, HQ | 1 |
| Ding, M | 1 |
| Feng, N | 1 |
| Tang, D | 1 |
| Li, Z | 1 |
| Jia, M | 1 |
| Liu, Z | 1 |
| Gu, X | 1 |
| Fu, F | 1 |
| Pei, J | 1 |
| Zhou, H | 1 |
| Yue, Y | 1 |
| Wang, J | 1 |
| Ma, Q | 1 |
| Chen, Y | 1 |
| Zhao, Z | 1 |
| Feng, X | 1 |
| Xiong, Z | 1 |
| Fan, Y | 1 |
| Behram Kandemir, Y | 1 |
| Guntekin, Ü | 2 |
| Tosun, V | 2 |
| Korucuk, N | 1 |
| Bozdemir, MN | 1 |
| Kandemir, YB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04784754] | Phase 2 | 0 participants (Actual) | Interventional | 2021-04-01 | Withdrawn (stopped due to lack of subject enrollment) | ||
| A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04474483] | Phase 2 | 8 participants (Actual) | Interventional | 2020-11-06 | Terminated (stopped due to difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for melatonin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
New insights into the role of melatonin in diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Endoplasmic Reticulum Stress; Humans; | 2022 |
Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathy.
Topics: Animals; Cardiovascular Agents; Diabetic Cardiomyopathies; Heart; Humans; Melatonin; Myocardium; Sig | 2020 |
9 other studies available for melatonin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Gene Ex | 2020 |
Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control: Role of SIRT6.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2021 |
Melatonin protects against diabetic cardiomyopathy through Mst1/Sirt3 signaling.
Topics: Animals; Diabetic Cardiomyopathies; Gene Expression Regulation; Hepatocyte Growth Factor; Macrolides | 2017 |
Melatonin ameliorates myocardial apoptosis by suppressing endoplasmic reticulum stress in rats with long‑term diabetic cardiomyopathy.
Topics: Animals; Apoptosis; Biomarkers; Blood Glucose; Diabetic Cardiomyopathies; Disease Models, Animal; En | 2018 |
Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dynamins; Melatonin; | 2018 |
Melatonin therapy for diabetic cardiomyopathy: A mechanism involving Syk-mitochondrial complex I-SERCA pathway.
Topics: Animals; Apoptosis; Calcium; Caspase 9; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; | 2018 |
Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition.
Topics: Animals; Apoptosis; Autophagosomes; Diabetic Cardiomyopathies; Disease Models, Animal; Hepatocyte Gr | 2018 |
Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition.
Topics: Animals; Apoptosis; Autophagosomes; Diabetic Cardiomyopathies; Disease Models, Animal; Hepatocyte Gr | 2018 |
Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition.
Topics: Animals; Apoptosis; Autophagosomes; Diabetic Cardiomyopathies; Disease Models, Animal; Hepatocyte Gr | 2018 |
Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition.
Topics: Animals; Apoptosis; Autophagosomes; Diabetic Cardiomyopathies; Disease Models, Animal; Hepatocyte Gr | 2018 |
Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A).
Topics: Animals; Antioxidants; Blood Glucose; Cardiotonic Agents; Coronary Vessels; Diabetic Cardiomyopathie | 2018 |
Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Male; Melatonin; Rats; Rats, Wi | 2019 |